skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Review

(2399) Views  (1156) Full article downloads

Authors: Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Published Date August 2010 Volume 2010:6 Pages 671 - 690
DOI: http://dx.doi.org/10.2147/VHRM.S4852

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, and the Texas Diabetes Institute, San Antonio, Texas, USA

Abstract: Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atherosclerotic and cardiovascular events. Glucagon-like peptide-1 deficiency/resistance contributes to islet cell dysfunction by impairing insulin secretion and increasing glucagon secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors improve pancreatic islet function by augmenting glucose-dependent insulin secretion and decreasing elevated plasma glucagon levels. Alogliptin is a new DPP-4 inhibitor that reduces glycosylated hemoglobin (HbA1c), is weight neutral, has an excellent safety profile, and can be used in combination with oral agents and insulin. Alogliptin has a low risk of hypoglycemia, and serious adverse events are uncommon. An alogliptin–pioglitazone combination is advantageous because it addresses both insulin resistance and islet dysfunction in T2DM. HbA1c reductions are significantly greater than with either monotherapy. This once-daily oral combination medication does not increase the risk of hypoglycemia, and tolerability and discontinuation rates do not differ significantly from either monotherapy. Importantly, measures of beta cell function and health are improved beyond that observed with either monotherapy, potentially improving durability of HbA1c reduction. The alogliptin–pioglitazone combination represents a pathophysiologically sound treatment of T2DM.

Keywords: diabetes, pioglitazone, incretins, DPP-4 inhibitors, alogliptin






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome
Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?
Aliskiren and valsartan combination therapy for the management of hypertension
Investigation of the antibacterial activity of pioglitazone
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University